$Viracta Therapeutics (VIRX.US)$ RBC Capital Sticks to Their...
$Viracta Therapeutics(VIRX.US$ RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
RBC Capital analyst Gregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.
According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA Pharmaceuticals, and Verastem.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viracta Therapeutics with a $9.25 average price target, a 556.03% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
VIRX market cap is currently $54.16M and has a P/E ratio of -1.02.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
Read More on VIRX:
• Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
• Viracta Therapeutics announces publication of study of Nana-val
• Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
• Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medi
RBC Capital analyst Gregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.
According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA Pharmaceuticals, and Verastem.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viracta Therapeutics with a $9.25 average price target, a 556.03% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
VIRX market cap is currently $54.16M and has a P/E ratio of -1.02.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.
Read More on VIRX:
• Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
• Viracta Therapeutics announces publication of study of Nana-val
• Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
• Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medi
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
